{"id":25426,"date":"2022-09-26T22:17:00","date_gmt":"2022-09-26T14:17:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25426"},"modified":"2025-02-04T22:24:25","modified_gmt":"2025-02-04T14:24:25","slug":"shuangcheng-pharma-licenses-us-rights-for-paclitaxel-injection-to-meitheal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25426","title":{"rendered":"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal"},"content":{"rendered":"\n<p>China\u2019s Hainan Shuangcheng Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/002693:SHE\">SHA: 002693<\/a>) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng\u2019s paclitaxel for injection (albumin-bound, 100mg\/vial) in the US market. Meitheal will be responsible for market planning and sales of the paclitaxel (albumin-bound) injection in the US, while Hong Kong King-Friend Industrial Co., Ltd (HKF) will pay a one-time milestone payment of $6 million.<\/p>\n\n\n\n<p><strong>Paclitaxel (Albumin-Bound) Overview<\/strong><br>Paclitaxel (albumin-bound) is a nanoparticle formulation produced by encapsulating paclitaxel with albumin. Originally developed by Celgene, Shuangcheng\u2019s generic version is currently awaiting regulatory decisions in China. Compared to other paclitaxel drugs, the cytotoxic side effects of paclitaxel (albumin-bound) are significantly reduced, allowing for higher dosing and enhanced anti-tumor effects. Additionally, the drug can accumulate in tumors and be released to tumor cells in a targeted manner, further improving its efficacy.<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>The licensing agreement with Meitheal Pharmaceuticals and Hong Kong King-Friend Industrial Co., Ltd marks a significant step for Shuangcheng Pharmaceutical in expanding its global footprint. By leveraging Meitheal\u2019s market planning and sales capabilities, Shuangcheng aims to bring its innovative paclitaxel formulation to the US market, addressing significant unmet needs in cancer treatment.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,16,31,3539,3538,3320],"class_list":["post-25426","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-cancer","tag-generic-drugs","tag-meitheal-pharmaceuticals","tag-sha-002693","tag-shuangcheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng\u2019s paclitaxel for injection (albumin-bound, 100mg\/vial) in the US market. Meitheal will be responsible for market planning and sales of the paclitaxel (albumin-bound) injection in the US, while Hong Kong King-Friend Industrial Co., Ltd (HKF) will pay a one-time milestone payment of $6 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25426\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25426\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T14:17:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-04T14:24:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25426#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25426\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal\",\"datePublished\":\"2022-09-26T14:17:00+00:00\",\"dateModified\":\"2025-02-04T14:24:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25426\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Cancer\",\"Generic drugs\",\"Meitheal Pharmaceuticals\",\"SHA: 002693\",\"Shuangcheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25426#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25426\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25426\",\"name\":\"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-09-26T14:17:00+00:00\",\"dateModified\":\"2025-02-04T14:24:25+00:00\",\"description\":\"China\u2019s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng\u2019s paclitaxel for injection (albumin-bound, 100mg\\\/vial) in the US market. Meitheal will be responsible for market planning and sales of the paclitaxel (albumin-bound) injection in the US, while Hong Kong King-Friend Industrial Co., Ltd (HKF) will pay a one-time milestone payment of $6 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25426#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25426\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25426#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng\u2019s paclitaxel for injection (albumin-bound, 100mg\/vial) in the US market. Meitheal will be responsible for market planning and sales of the paclitaxel (albumin-bound) injection in the US, while Hong Kong King-Friend Industrial Co., Ltd (HKF) will pay a one-time milestone payment of $6 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25426","og_locale":"en_US","og_type":"article","og_title":"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25426","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-09-26T14:17:00+00:00","article_modified_time":"2025-02-04T14:24:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25426#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25426"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal","datePublished":"2022-09-26T14:17:00+00:00","dateModified":"2025-02-04T14:24:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25426"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Cancer","Generic drugs","Meitheal Pharmaceuticals","SHA: 002693","Shuangcheng Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25426#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25426","url":"https:\/\/flcube.com\/?p=25426","name":"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-09-26T14:17:00+00:00","dateModified":"2025-02-04T14:24:25+00:00","description":"China\u2019s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng\u2019s paclitaxel for injection (albumin-bound, 100mg\/vial) in the US market. Meitheal will be responsible for market planning and sales of the paclitaxel (albumin-bound) injection in the US, while Hong Kong King-Friend Industrial Co., Ltd (HKF) will pay a one-time milestone payment of $6 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25426#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25426"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25426#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25426"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25426\/revisions"}],"predecessor-version":[{"id":25428,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25426\/revisions\/25428"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}